"The good news is that: 1. No one knows when either the trial will commence or a label extension will be granted. 2. It would only impact 8 out of 29 sites CYP is recruiting from."
1. I've shown you before. FDA approval has been granted. The label extension decision lies in the hands of doctors and patients (and potentially insurance companies, which is highly likely). Doctors like Dr. Joanne Kurtzberg, who is a world leader. The word in that world is out already. Adults with the disease will wait for Cynata and the results of the P2 and then a P3 (via 'the FDA under Marks')? I haven't got a link to show, but I do have a brain. You are not thinking that a P3 won't be necessary, are you? 2. Lithuania and Turkey are not likely to be affected by this Mesoblast inconvenience. Whew!
CYP Price at posting:
22.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)